You are here

Making a Difference for Patients

At Pfizer, while our goal is to save and improve lives through the development of innovative medicines and vaccines, we equally value the impact we can have on empowering patients to once again live the fullest life possible. It is with that in mind that we will continue to forge new partnerships and improve our current ones, look to develop new healthcare innovations that provide more holistic value to patients, work with governments, payers and nongovernment organizations to ensure the widest access to medicines possible, continue to enhance the way we integrate patient insights into our research and development, and finally, increase the number of programs that educate and empower patients to participate in their healthcare decisions. We believe all of these goals are only possible by working in partnership with patients and putting them and their needs at the center of everything we do.

A LENS ON LIFE

A Lens on Life is an unscripted docuseries that chronicles the stories of women and men living with various health challenges.

 

HIGHLIGHTS

Pfizer's impact is making a difference for patients and helping to change the future of global health.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-unique-partnership.jpg

Body (2nd column): 

A UNIQUE PARTNERSHIP

“By co-developing solutions that deliver greater value to both patients and healthcare systems, the ambition is to export these to other regions and countries and transform how we collaborate with governments and healthcare stakeholders to improve health around the world. We look forward to working together with our partners in the U.K. and Pfizer's IMPACT Accelerator team to advance this collaboration, reflecting our Patients First ambitions.”
- Eric Nordkamp, Country Manager, U.K., Pfizer Internal Medicine, International Developed Markets

Pfizer U.K. recently announced a unique public-private partnership to improve the health and well-being of people in the Swansea Bay City Region in Wales, U.K. The consortium includes the local city council, the devolved Welsh Government, academia, healthcare providers, and multinational technology and medical device companies. Pfizer is committed to a multiyear relationship to develop a “living laboratory,” including participation in a physical health and life sciences village environment, which will enable testing and learning of how real world and clinical interventions can help the local population to achieve improved outcomes and scale those solutions to other markets.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-commitment-to-helping-others.jpg

Body (2nd column): 

Commitment to Helping Others

"Advocacy work for me is 24/7. My life is never about me anymore; it's all about who I can help."
- Sheila McGlown

Sheila McGlown is a mother, wife, veteran of the U.S. Air Force, metastatic breast cancer (MBC) patient and advocate. For Sheila, the fight against breast cancer goes beyond her personal battle with the disease: Her mother passed away from MBC in 2004. One of the goals of her advocacy work is to raise awareness that MBC can affect anyone, regardless of race or age.

Learn more about Sheila's story >>

Layout option: 
2 column (Small left and large right).
Body: 

highlight-living-with-cancer.jpg

Body (2nd column): 

This is Living With CancerTM Program

"Cancer patients can feel isolated and unsure about how to navigate care and approach day-to-day life. Pfizer's new programming that goes beyond treatment is critical in helping patients and their care networks deal with the challenges associated with living with cancer."
- Myra Biblowit, President & CEO, Breast Cancer Research Foundation

Pfizer Oncology launched This is Living with CancerTM, a program that shares inspiring stories and provides people living with cancer and their loved ones resources, including a free mobile app, called Living WithTM.

Click here to learn more about this campaign ».

Layout option: 
2 column (Small left and large right).
Body: 

highlight-ulcerative-colitis.jpg

Body (2nd column): 

Ulcerative Colitis Narrative Survey

"I'm excited to be a part of the UC Narrative because I would like my past experience and my journey to help a newly diagnosed patient or someone who feels alone."
- Jordan, UC Patient

The Crohn's & Colitis Foundation, IBD thought leaders and ulcerative colitis (UC) patients joined Pfizer to announce preliminary findings of the U.S. portion of the global UC Narrative survey. The survey, conducted with 301 U.S. adults with UC and 149 gastroenterologists, found that symptoms may impact patients' life choices, such as having children. Global results will be released in the spring.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-voice-for-choice.jpg

Body (2nd column): 

Voices for Choice Platform

"Pfizer has a longstanding history of delivering life-changing medications to patients. Through the Voices of Choice platform, we hope to continue to showcase the value our medications provide and highlight the importance of freedom of physician and patient choice in biosimilar and biologic treatment decisions."
- Angela Lukin, Regional President, International Developed Markets, Pfizer Inflammation & Immunology

Pfizer Inflammation & Immunology and Pfizer Essential Health Biosimilars recently joined forces to launch Voices for Choice, a new platform aimed at underscoring the importance of maintaining physician and patient choice of treatments. It was created to educate people on biosimilars and biologics and to challenge common misconceptions associated with these two types of medicines.

Layout option: 
2 column (Small left and large right).
Body: 

Hemo-Heroes

Body (2nd column): 

HemoHeroes App

"Supporting patients in understanding their condition is a key aspect of our patient-centric approach, so we are very excited to launch this fantastic program in the Middle East. The game is specifically designed to resonate with little ones, helping them and their families really understand the merit of a healthy lifestyle and the importance of treatment compliance."
- Mohamed FawzyPIH Gulf Cluster Lead, Gulf States,Emerging Markets

Pfizer, in partnership with the Friends of Hemophilia Society, launched the new HemoHeroes app last month in Qatar to encourage young patients to be more aware of their condition and learn how to best manage and treat it. Patients navigate life ina digital world, doing everyday things like cooking, exercising, bathing and bedtime and are prompted along the way to think about healthy eating, hygiene, exercise and avoiding hazards.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-take-time-take-action.jpg

Body (2nd column): 

Take Time, Take Action for Rheumatoid Arthritis Patients

"Take Time, Take Action has heightened our commitment to patients with rheumatoid arthritis. I am so proud to see the passion of our Pfizer Inflammation & Immunology colleagues coming to life in this way."
- Angela Lukin, Regional President, International Developed Markets, Pfizer Inflammation & Immunology

Take Time, Take Action is an initiative in which Pfizer colleagues from across the International Developed Markets have been "taking action" for rheumatoid arthritis patients – 160 colleagues, 200 hours and 12 activities. From the Netherlands to New Zealand, Pfizer colleagues are fundraising, completing personal challenges such as running a 10K, or working with nonprofit organizations to show their commitment to patients with rheumatoid arthritis.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-tech-and-aging.jpg

Body (2nd column): 

Technology, Self-Care and Aging

"Consumers are living longer, and as they age, they are looking for innovative ways to take health and wellness into their own hands. Leveraging technology enables us to increase communication between practitioners and patients, and drive self-care in home environments."
- Peter Ramsey, Senior Vice President, Global Health, Pfizer Consumer Healthcare

Peter Ramsey, Pfizer Consumer Healthcare's Global Health Lead, recently led an interactive session to discuss trends in consumer behavior and how technology empowers consumers to practice self-care at the International Association of Gerontology and Geriatrics (IAGG) World Congress. Joining Peter for the panel discussion were representatives from the Gallup Organization, Walmart, Samsung and PricewaterhouseCoopers.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-why-everyone-counts.jpg

Body (2nd column): 

Why Everyone Counts for Rare Disease

"From a patient's first perspective, I really think that it needs to be a true understanding. Pfizer is constantly reaching out to understand and to help in any way possible, and I think it is a true partnership and I think that needs to continue."
- Kyle B., Friedreich's Ataxia Patient

Kyle has Friedreich's Ataxia, a rare autosomal recessive inherited disease that causes progressive damage to the nervous system. He is the founder and director of rideATAXIA, which fundraises for Friedreich's Ataxia Research Alliance (FARA). Kyle is the current spokesperson for FARA and has completed two cross-country cycling adventures for FARA.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-sickle-cell.jpg

Body (2nd column): 

Sickle Cell Disease Awareness

"I'm honored to participate in the NNPA annual convention. Through our collaboration, we aim to further educate the African-American community about SCD in an effort to improve the quality of care."
- Kevin Williams, Chief Medical Officer, Pfizer Rare Disease

Pfizer Rare Disease Chief Medical Officer, Kevin Williams, spoke about Sickle Cell Disease (SCD) and Pfizer's collaboration with the National Newspaper Publishers Association (NNPA), an association of more than 200 African-American-owned newspapers, at their annual convention. Nearly 100 NNPA publishers attended this session, which included an engaging Q&A session where audience members expressed interest in topics including SCD clinical trials and pain management.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-helping-people-hemo.jpg

Body (2nd column): 

Helping People Living With Hemophilia

"At Pfizer, we work to meet their ever-changing needs. Our hope is that new technologies make meaningful differences for the approximately 20,000 people living with hemophilia in the U.S."
- Jack Kelleher, Global Business Technology Lead, Pfizer Rare Disease

We recently launched two digital innovations at the National Hemophilia Foundation annual meeting: Hemocraft, a modification of the popular video game Minecraft®, and the HemMobile® Striiv® Wearable, a custom wristband, to help people living with hemophilia better approach hemophilia education and activity tracking in the U.S.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-vaccine-stories.jpg

Body (2nd column): 

Vaccination Stories

"I'm the person that didn't know about MenB and was lucky enough to be able to get the vaccine for my kids. I want people to be as lucky as I am."
- Shirley Pyburn, mother of two students who attended a university during a MenB outbreak

Patti, Meredith, and Shirley are three moms whose families have been impacted by meningococcal group B disease, or MenB. While Patti and Meredith lost their children, Shirley was able to get her two sons vaccinated during an outbreak at their college. The moms united to tell their stories in honor of World Meningitis Day and encourage others to Stand In-B-Tween their children and MenB.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-awareness-of-invasive.jpg

Body (2nd column): 

Awareness of Invasive Pneumococcal Disease (IPD)

"It's really important to help protect children, especially young children, by staying up to date on their vaccinations in accordance with the CDC guidelines."
- Dr. Jen Trachtenberg, Board-Certified Pediatrician, Parenting Expert, and Contributor to Parents magazine

Pfizer recently partnered with Parents magazine to raise awareness of invasive pneumococcal disease (IPD) and share results from a survey of more than 2,000 new and expectant parents assessing their knowledge of childhood infectious diseases, including IPD. Notably, only three of every 10 (30 percent) parents surveyed report they are knowledgeable about IPD.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-data-education.jpg

Body (2nd column): 

Data, Education and Action: AFib Screening Research

"These activities continue to demonstrate how we're committed to the patient – first and foremost – by ensuring important research and insights make it to their HCPs."
- Rory O'Connor, Chief Medical Officer, Pfizer Internal Medicine

At the recent European Society of Cardiology (ESC) in Barcelona, an abstract from research commissioned by the Pfizer-BMS Alliance revealed that the majority of people aged 65 and older are not screened for AFib during routine primary care examinations, despite this population’s high risk – another actionable insight reflecting our partnerships and our passion.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-working-prevent-afib.jpg

Body (2nd column): 

Working to Prevent AFib Related Stroke

"People with AFib are at least three times more likely to have a stroke than those without this condition. Even modest improvements in diagnosis and treatment of stroke risk factors including AFib – supported by collaborations across healthcare providers, advocates, policymakers and the private sector – could potentially prevent many strokes and related deaths."
- Masum Hossain, Vice President, Global Marketing, Pfizer Internal Medicine

The Bristol-Myers-Squibb-Pfizer Alliance recently sponsored the Preventing Stroke: Uneven Progress report, which was released by The Economist Intelligence Unit (EIU), the research and analysis division of The Economist Group and the world leader in global business intelligence. The report revealed that on average, more than 75 percent of people aged 65 and older worldwide are not being screened for atrial fibrillation (AFib) and other common stroke risk factors during routine primary care examinations, even though this population is at high risk for stroke. The analysis of 20 countries found that efforts to screen people for stroke risk factors including AFib and hypertension varied widely, even in countries with established healthcare and developed economies.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-personal-story.jpg

Body (2nd column): 

A Personal Story of Stroke, Recovery and Advocacy

"Pfizer, you have the ability to help people around the world and I applaud that, I applaud that a lot. Never forget that. Never forget that people like me are counting on people like you."
- Mark M., Stroke Patient

A former journalist and television news personality, Mark suffered a stroke in 2005. He serves as Ambassador for the American Heart Association's “Power To End Stroke” and speaks around the country sharing his personal journey.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-advocacy-summit-.jpg

Body (2nd column): 

Advocacy Summit to Treat Tobacco Dependence in the E.U.

"It is clear that this global health epidemic can only be addressed and ultimately stopped if we work together, if we collectively create synergies to achieve advancements in tobacco control policies, and if we provide access to smoking cessation services and therapies."
- Beatriz Faro, Regional President, International Developed Markets, Pfizer Internal Medicine

In June 2017, in Madrid, Pfizer gathered tobacco control experts, representatives of patient groups, medical societies and nongovernmental organizations from eight countries in the European Union to discuss a coordinated approach to elevate the treatment of tobacco dependence to a public health priority. By bringing together a cross section of these influential groups, Pfizer was able to advance the discussion on access challenges related to smoking-cessation treatment in Europe.

Layout option: 
2 column (Small left and large right).
Body: 

highlight-advocacy-summit-.jpg

Body (2nd column): 

Connecting Patients to Financial Support and Savings

“It was just an awesome feeling to know that there was somebody, a company as huge as Pfizer, helping a little person here in North Carolina like me.”
- Terry, helped by Pfizer RX Pathways

Terry needed help accessing his medication and wasn’t sure where to go. After researching his options, he learned about Pfizer RxPathways®, which connects eligible patients to Pfizer and industry programs that offer insurance support, co-pay assistance, medicines for free or at a savings, and more.

Learn more about Pfizer Rx Pathways>>

Layout option: 
2 column (Small left and large right).
Body: 

bottom-tile-putting-patients-first.jpg

Body (2nd column): 

Putting Patients First
Patients are at the center of what we do.
Learn More »

Layout option: 
2 column (Small left and large right).
Body: 

bottom-tile-engaging-patients.jpg

Body (2nd column): 

Engaging Patients
For patients, with patients.
Learn More »

Layout option: 
2 column (Small left and large right).
Body: 

bottom-tile-fostering-partnerships.jpg

Body (2nd column): 

Fostering Meaning Partnership
Working together to help patients live longer, healthier lives.
Learn More »